As a result, all of the variants from the previous study were excluded (Supplementary Fig. 1, Additional file 1), since they either did not occur in the new obligate carrier (eight variants in the genes DZIP1L, PCOLCE2, IGSF10, SUCNR1, OR13C8, TAS2R7, SF3A1 and TRIOBP), or were present in the local breast cancer cohort (three variants in the genes GAL3ST1, SEC16A and NOTCH1), or did not pass the new quality control (one variant in the gene EPB41L4B). This evidence concerns the gene SF3A1 and breast cancer.